[68ga]ga-nodaga-sna014
Peptideexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 20, 2024 (NCT06646783)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Fibronectin receptor betaRadiopharmaceutical
ITGB1 radiopharmaceutical
Chemistry & pharmacology
- Payload
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06646783 | Early Phase 1 (Phase 1) | Oct 20, 2024 | SmartNuclide Biopharma |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SmartNuclide Biopharma | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1